Although infusion of cryopreserved bone marrow or peripheral blood stem cell is associated with a variety of symptoms, there have been no reports detailing the data of infusion-related toxicities of cryopreserved cord blood (CB) units. We prospectively evaluated the incidence and significance of infusion-related toxicities in 34 adult patients undergoing unrelated CB transplantation. Cryopreserved CB units were thawed and immediately infused, unfiltered, through a central intravenous catheter without further manipulation. Heart rate, blood pressure, oxygen saturation and clinical symptoms were recorded during and after infusion. Twenty-four percent of patients experienced non-cardiovascular toxicities related to infusion. The incidence of systolic and diastolic hypertension and bradycardia was 58, 64 and 32%, respectively. Although three patients (9%) with severe systolic hypertension after the infusion required treatment with antihypertensive agents, no patients experienced lifethreatening side effects or needed discontinuation of CB unit infusion. Patient or transplant characteristics had no effect on the hypertension and bradycardia related to the infusion of CB. These data suggest that infusion of cryopreserved CB without further manipulation after thawing is safe and well tolerated. However, cardiovascular toxicities including hypertension and bradycardia were frequently observed.
Introduction
Recently, umbilical cord blood (CB) has been used as an alternative source of hematopoietic stem cells in unrelated allogeneic transplantation in adult patients without a human leucocyte antigen (HLA)-matched, related or unrelated donor. [1] [2] [3] [4] [5] [6] The increasing use of CB for transplantation initiated the establishment of CB banks in many parts of the world. CB cells are usually added to a cryoprotective agent and frozen in liquid nitrogen until thawing and transfusion, because the time interval between collection of CB and transplantation is several months or years. In almost all CB banks, CB cells are cryopreserved in dimethylsulfoxide (DMSO) and RBCs are depleted. 7 In autologous transplantation with cryopreserved bone marrow (BM) or peripheral blood stem cells (PBSCs), infusion of thawed products has been accompanied by a wide variety of symptoms including nausea, vomiting, hypertension, hypotension and bradycardia. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Adverse events are usually mild to moderate and, very rarely, various life-threatening events have been reported. As there have been no reports detailing the data on infusion-related toxicities of CB transplantation (CBT), we prospectively evaluated the incidence and significance of infusion-related toxicities in 34 adult patients undergoing unrelated CBT for hematological malignancies.
Patients and methods

Patients
We prospectively evaluated infusion-related toxicities in 34 patients undergoing unrelated CBT between March 2006 and September 2007 at the Institute of Medical Science, University of Tokyo (Tokyo, Japan). Written informed consent for treatment was obtained from all patients. Twenty-one patients were transplanted for acute myeloid leukemia, eight for acute lymphoblastic leukemia, three for myelodysplastic syndrome, one for chronic myeloid leukemia and one for chronic active Epstein-Barr virus infection. The median age at transplantation was 41 years (range, 16-59), the median weight was 58 kg (range, 39-76), the median number of cryopreserved nucleated cells was 2.37 Â 10 7 /kg (range, 1.73-5.15) and the median number of cryopreserved CD34-positive cells was 0.82 Â 10 5 /kg (range, 0.28-2.84). The median cumulative dose of adriamycin before CBT was 183 mg/m 2 (range, 0-586). Nineteen of the patients were male and 15 female. Six patients had received two or more CBTs because of disease relapse after the preceding CBT (Table 1) . Two patients had hypertension before transplantation and were treated with an antihypertensive drug.
Conditioning regimens and prophylaxis against graft-versus-host disease Twenty-seven patients received 12 Gy total body irradiation (TBI) and chemotherapy as myeloablative conditioning. Two patients received busulfan and cyclophosphamide at standard doses. Five patients received 2-4 Gy TBI and chemotherapy as reduced intensity conditioning (Table 1) . Twenty-seven patients received standard cyclosporine (CYA) and methotrexate, two received CYA only and five received CYA and mycophenolate mofetil as graft-versushost disease prophylaxis.
Cord blood processing
Cord blood units in this study were obtained from Hokkaido
and Fukuoka Red Cross (n ¼ 3) CB banks, which belong to Japan Cord Blood Network (JCBNW). The methods of collecting, processing and cryopreservation varied among CB banks. In JCBNW, the final volume of the processed CB units was approximately 25 ml and the final concentration of DMSO was 10%, although it was 5% in the Hyogo CB Bank.
Cord blood infusion
Thirty minutes before CB infusion, patients were premedicated with 100 mg of hydrocortisone and 25 mg of hydroxyzine. The cryopreserved CB cells were thawed in a water bath at 37 1C and immediately drawn into a syringe and infused, unfiltered, through a central intravenous catheter over 5-15 min without additional manipulation. Cell viability was determined by staining with ethidium bromide and acridine orange at the time of thawing, as reported previously. 19 Stained cells were counted under a fluorescence microscope.
Patient monitoring
All patients were monitored by telelectrocardiogram starting before infusion until approximately 6 h after CBT. Heart rate, blood pressure and oxygen saturation were recorded every 5 min during infusion, every 30 min for 2 h after infusion and every hour during the following 4 h. Clinical symptoms were also recorded. Blood pressure elevation was defined as an increment of more than 20% from the baseline value at the beginning of infusion. Bradycardia was defined as reduction of the heart rate to below 60 beats/min.
Statistical analysis
Data analysis was performed with statistical computer software (JMP, SAS Institute, Cary, NC, USA). The following variables were considered as covariates related to cardiovascular or non-cardiovascular adverse events: conditioning regimen, the cumulative dose of adriamycin before CBT, age of patient, body weight at transplant, the number of cryopreserved total nuclear cell count infused, the number of dead cells infused after thawing, the volume of infused CB products, the dose of infused DMSO and ABO incompatibility between donor and recipient. All P-values were two-tailed and P-values less than 0.05 were considered to be statistically significant.
Results
The median cryopreserved total nucleated cell count was 13.70 Â 10 8 (range, 10.89-22.56), the median cryopreserved CD34-positive cell count was 4.80 Â 10 6 (range, 2.15-12.15) and the median number of cryopreserved colony-forming unit-granulocyte-macrophage was 11.64 Â 10 5 (range, 3.05-63.03). The median volume of CB product infused was 25.45 ml (range, 24.9-27.6). The median duration of CB infusion was 17 min (range, 5-30). The median viability after thawing was 79.2% (range, 59.2-89.7). The number of HLA disparities was defined as low resolution for HLA-A and HLA-B and high resolution for HLA-DRB1. Five patients received 5/6, 17 received 4/6, 10 received 3/6 and 2 received 2/6 matched CB units. Thirteen donor-recipient pairs were ABO identical, eight had a minor mismatch, eight had a major mismatch and five had a bidirectional ABO mismatch. The presence of sex mismatch between donor and recipient was documented in 15 patients. Cardiovascular changes associated with the CB infusions are presented in Table 2 . Nineteen patients (56%) experienced a decrease in heart rate of 20% from the baseline with a mean of 20.4 beats/min (95% confidence interval (CI): 16.9-23.8; range, 4-38). Eleven patients (32%) developed bradycardia. The median time from the beginning of CB infusion to the minimum value in heart rate was 90 min (range, . No cases of heart block were observed. Chest discomfort was not noticed in patients with bradycardia. All patients with bradycardia recovered spontaneously with no treatment. Three patients developed extrasystolic arrhythmias, of which two were premature ventricular contractions and one premature atrial contraction. Thirty-three (97%) patients showed an increase in systolic blood pressure, with a mean increment of 28.9 mm Hg (95% CI: 22.4-35.3; range, 2-102). Twenty (58%) patients experienced an increase in systolic blood pressure of 20% from the baseline. Thirty-three (97%) patients showed an increase in diastolic blood pressure with a mean increment of 17.8 mm Hg (95% CI: 14.3-21.3; range, 0-40). Twenty-two (64%) patients experienced an increase in diastolic blood pressure of 20% from the baseline. Maximum systolic blood pressure value was observed during infusion in 12 patients and after infusion in 22 patients. Only three patients with systolic blood pressure more than 180 mm Hg required antihypertensive drug, such as nifedipine (5 mg) with prompt improvement. The non-cardiovascular symptoms experienced by these patients are presented in Table 2 . Nausea and vomiting occurred in three (9%), chest discomfort in two (6%) and headache in two (6%) patients. Asymptomatic desaturation (reduction in O 2 saturation below 95%) occurred in two (6%) patients. Almost all patients had grade 1 or 2 noncardiovascular toxicities according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3. There were no differences in groups with and without hypertension, bradycardia and non-cardiovascular toxicities regarding the conditioning regimen, cumulative dose of adriamycin before CBT, age of patient, body weight at transplant, the number of cryopreserved total nuclear cell count infused, the number of dead cells infused after thawing, the volume of infused CB products, the dose of infused DMSO and ABO incompatibility between donor and recipient (Tables 3-5) . A trend toward development of bradycardia was observed in older patients, but this did not reach statistical significance (P ¼ 0.06).
Discussion
This study demonstrates that cardiovascular complications are major adverse events relating to infusion of cryopreserved CB units. We found that 79% of patients experienced adverse events related to infusion of CB units. The incidence of systolic and diastolic hypertension and bradycardia was 58, 64 and 32%, respectively. Although three patients (9%) with severe systolic hypertension after the infusion required antihypertensive drug, no patient experienced life-threatening side effects and discontinued infusion of CB units in this study. Three patients with severe systolic hypertension after the infusion were 55 years of age or older. However, our data do not suggest that hypertension is related to patient age. Bradycardia was usually self-limiting and recovered within 6 h after CB infusion in our study, although bradycardia has been rarely reported up to 12 h after infusion of cryopreserved PBSCs monitored by 24 h Holter recording. 20 On the basis of these results, it can be concluded that infusion of unmanipulated CB units is safe and well tolerated. There are few reports on infusion-related toxicity of CB. [21] [22] [23] McKenna et al. 21 reported that 49% of patients receiving CBT developed adverse events associated with infusion of CB. Hypertension and bradycardia were Table 3 Patients and CB product characteristics according to hypertension Abbreviation: CB ¼ cord blood. a Hypertension was defined as an increment of more than 20% from the baseline value at the beginning of infusion. b Bradycardia was defined as reduction of heart rate under 60 beats/min. c Desaturation was defined as reduction of oxygen saturation under 95%.
reported in 24 and 2% of patients, respectively. Hahn et al. 22 reported that 22% of patients receiving unmanipulated CB infusion had adverse events including nausea, increased blood pressure, decreased heart rate and other symptoms. However, these two reports did not detail the definition of hypertension or bradycardia. Therefore, the infusion-related cardiovascular toxicity of CB is not well defined. The present study suggests that infusionrelated cardiovascular toxicities are more frequent in CBT than in autologous BM or PBSC transplantation. The mechanisms of cardiovascular toxicity during CB infusion remained unclear. Various factors might contribute to the development of cardiovascular toxicity during autologous BM or PBSC infusion. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] These include dose of DMSO, cell lysis products, RBC content, total nuclear cell content, acute volume expansion, age of patient and chemotherapeutic agents used before transplantation. The thawed CB product contained dead cells, which was evaluated by staining with ethidium bromide and acridine orange at the time of thawing. However, the number of dead cells infused after thawing did not have any effect on cardiovascular toxicities during infusion of CB units. In this study, most CB units were cryopreserved in 10% DMSO and the dose of infused DMSO did not have any effect on infusionrelated toxicities. Although only a small amount of DMSO is infused, the associated hyperosmolality may cause adverse effects. Syme et al. 24 reported that the depletion of DMSO from autologous PBSC before infusion could decrease infusion-related toxicity. In our study, the cryopreserved CB cells were infused without further manipulation. Therefore, the role of depleting DMSO before CB infusion should be investigated further in view of infusion-related cardiovascular toxicity. 
